Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec Achieves First Milestones in Multi-target Deal with UCB

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
Projects move into hit-to-lead and lead optimization.

Evotec AG has announced that it has achieved first milestones in its multi-year, multi-target integrated drug discovery collaboration with UCB in the field of immunology.

The milestones were achieved upon the progression of certain projects into hit-to-lead and into lead optimization.

Evotec and UCB entered into this collaboration in October 2011. Under the terms of the collaboration, Evotec receives research payments, milestones based on achieving various pre-clinical, clinical and sales goals and royalties on final product sales.

Dr Mario Polywka, Chief Operating Officer of Evotec, stated: 'We are delighted that the project teams at UCB and Evotec have met these important milestones in the collaboration. The progress in this collaboration is a testament to the way scientists from both companies have worked together in a true partnership.'

Dr Neil Weir, Senior Vice President of Discovery at UCB, commented that 'The collaboration with Evotec complements our internal research efforts and enhances our scientific network. Hitting these milestones is great news and as we continue to work together, we hope that the results will enhance the pace of the discovery process, the quality of compounds selected for further development and ultimately improve patient outcomes.'


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec and Sanofi Enter into Exclusive Negotiations
Goal to improve innovation effectiveness in drug discovery and pre-clinical development.
Thursday, December 04, 2014
Evotec Receives Milestone Payment as part of its Discovery Alliance with Boehringer Ingelheim
Company receives milestone payment of € 1.0 m.
Thursday, June 19, 2014
Evotec to Establish an Anti-infectives Platform with the Acquisition of Euprotec Ltd
Adds key know-how and infectious disease therapeutic area capabilities.
Thursday, May 29, 2014
Evotec Acquires UK-Based CRO Euprotec
Company announce the acquisition of all shares in Euprotec Ltd, a recognised leader in anti-infective drug discovery services
Thursday, May 29, 2014
Evotec Acquires Bionamics to Accelerate 'EVT Innovate' Strategy
Expanding discovery pipeline with portfolio of projects especially in Multiple Sclerosis and CNS.
Saturday, March 29, 2014
Evotec Receives Pre-Clinical Milestone with Boehringer Ingelheim
The milestone relates to the transition of an oncology molecule into pre-clinical development.
Tuesday, December 10, 2013
Evotec raises € 30 m from Biotechnology Value Fund
Biotechnology Value Fund, L.P. and other affiliates of US investment firm BVF partners L.P. (“BVF”) invest € 30 M in new Evotec shares.
Monday, September 02, 2013
Evotec Expands Collaboration with MedImmune
Evotec AG has expanded the scope of its collaboration with MedImmune after hitting a key milestone. Evotec achieved a milestone payment of €0.5 m.
Monday, January 07, 2013
Evotec Enters Biology Collaboration with Probiodrug
Evotec will setup and validate assays to support the pre-clinical and clinical development of QC inhibitors in Alzheimer’s disease.
Thursday, November 29, 2012
Evotec Extends Ongoing Collaboration with CHDI Foundation
Collaboration aims to accelerate development of drugs that slow the progression of Huntington's disease.
Monday, November 05, 2012
Evotec and Aspireo Enter into Strategic Advisory Agreement
Teaming up to partner Aspireo’s Somatoprim (DG3173).
Wednesday, October 03, 2012
Evotec and Bayer Enter into Multi-target Alliance to Fight Endometriosis
Companies have entered into a five-year, multi-target collaboration with the goal of developing three clinical candidates for the treatment of endometriosis.
Monday, October 01, 2012
Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
Company receives milestone payment of EUR 2.5 million.
Thursday, September 27, 2012
Evotec Receives Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
Company receives milestone payment of EUR 4.0 million.
Thursday, June 07, 2012
Evotec Receives Milestone as Boehringer Ingelheim Starts Phase I Clinical Trial in Pain
Evotec will receive a milestone payment of EUR 2.0 million.
Wednesday, June 01, 2011
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!